Literature DB >> 4371940

Pseudomembranous colitis associated with antibiotic therapy - an emerging entity.

S Fenton, D Stephenson, C Weder.   

Abstract

Two cases of pseudomembranous colitis are presented. The first patient had been treated with novobiocin-tetracycline and penicillin, and two weeks later developed severe fulminating diarrhea with ascites and bilateral pleural effusions which did not respond to intravenous ACTH. Subsequently she underwent subtotal colectomy and made a rapid and complete recovery. The second patient developed severe diarrhea two weeks after a 10-day course of clindamycin. She was treated with intravenous ACTH, oral Lactobacillus and a fecal enema and made a complete recovery.These cases reconfirm the importance of antibiotics as etiologic agents in this disease. They also stress the classic sigmoidoscopic and histologic findings that should facilitate prompt and rapid diagnosis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4371940      PMCID: PMC1955857     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  10 in total

1.  Generalized postoperative pseudomembranous enterocolitis.

Authors:  J D PETTET; A H BAGGENSTOSS; E S JUDD; W H DEARING
Journal:  Proc Staff Meet Mayo Clin       Date:  1954-06-16

2.  Pseudo-membranous colitis.

Authors:  S J Goulston; V J McGovern
Journal:  Gut       Date:  1965-06       Impact factor: 23.059

3.  Pseudomembranous colitis following aureomycin and chloramphenicol.

Authors:  L REINER; M J SCHLESINGER; G M MILLER
Journal:  AMA Arch Pathol       Date:  1952-07

4.  Pseudomembranous colitis: a consideration in the barium enema differential diagnosis of acute generalized ulcerative colitis.

Authors:  P M Shimkin; R J Link
Journal:  Br J Radiol       Date:  1973-06       Impact factor: 3.039

5.  Acute enterocolitis. A complication of antibiotic therapy.

Authors:  R L Schapiro; A Newman
Journal:  Radiology       Date:  1973-08       Impact factor: 11.105

6.  Clindamycin-associated colitis.

Authors:  L E Cohen; C J McNeill; R F Wells
Journal:  JAMA       Date:  1973-03-19       Impact factor: 56.272

7.  Diagnostic features of clindamycin-associated pseudomembranous colitis.

Authors:  F J Tedesco; R J Stanley; D H Alpers
Journal:  N Engl J Med       Date:  1974-04-11       Impact factor: 91.245

8.  Idiopathic pseudomembranous colitis successfully treated by surgical excision.

Authors:  B T Jackson; C J Anders
Journal:  Br J Surg       Date:  1972-02       Impact factor: 6.939

9.  Fulminating noninfective pseudomembranous colitis.

Authors:  A Groll; M J Vlassembrouck; S Ramchand; L S Valberg
Journal:  Gastroenterology       Date:  1970-01       Impact factor: 22.682

10.  Pseudomembraneous colitis as a sequel to oral lincomycin therapy.

Authors:  E J Benner; W H Tellman
Journal:  Am J Gastroenterol       Date:  1970-07       Impact factor: 10.864

  10 in total
  5 in total

Review 1.  Fecal microbiota transplantation and emerging applications.

Authors:  Thomas J Borody; Alexander Khoruts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-20       Impact factor: 46.802

2.  Antibiotic-associated pseudomembranous colitis.

Authors:  W R Bartle; F G Saibil
Journal:  Can Med Assoc J       Date:  1977-01-22       Impact factor: 8.262

3.  Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Authors:  Faith Rohlke; Neil Stollman
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 4.  Current challenges in the treatment of severe Clostridium difficile infection: early treatment potential of fecal microbiota transplantation.

Authors:  Yvette H van Beurden; Max Nieuwdorp; Pablo J E J van de Berg; Chris J J Mulder; Abraham Goorhuis
Journal:  Therap Adv Gastroenterol       Date:  2017-02-08       Impact factor: 4.409

Review 5.  Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond.

Authors:  Thomas J Borody; Debra Peattie; Scott W Mitchell
Journal:  Antibiotics (Basel)       Date:  2015-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.